Health Economics›Autologous HSCT›High dose therapy conditioning regimens all lines of therapy

High dose therapy conditioning regimens all lines of therapy

Autologous HSCT · 27 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-BEAM Variant #01 Partial	—	R 56 156	—	—	—	~1	~R 56 156 indirect	—
R-TBI/Cy Variant #01	—	R 52 985	—	—	—	~1	~R 52 985 indirect	—
Z-BEAM Variant #01 Partial	—	R 30 964	—	—	—	~1	~R 30 964 indirect	—
Bu/TT Variant #01 Partial	—	R 28 006	—	—	—	~1	~R 28 006 indirect	—
BeEAM Variant #01	—	R 18 312	—	—	—	~1	~R 18 312 indirect	—
CBV-Mx Variant #01 Partial	—	R 16 619	—	—	—	~1	~R 16 619 indirect	—
V-BEAM Variant #01 Partial	—	R 11 108	—	—	—	~1	~R 11 108 indirect	—
CBV Variant #01 Partial	—	R 9 597	—	—	—	~1	~R 9 597 PFS proxy · indirect	4
Cyclophosphamide, Etoposide, TBI Variant #01	—	R 9 597	—	—	—	~1	~R 9 597 indirect	—
Bu/TT/Cy Variant #01 Partial	—	R 9 578	—	—	—	~1	~R 9 578 indirect	—
LEED Variant #01	—	R 7 388	—	—	—	~1	~R 7 388 indirect	—
Bortezomib and Melphalan Variant #01	—	R 7 262	—	—	—	~1	~R 7 262 indirect	—
BEAC Variant #01 Partial	—	R 7 009	—	—	—	~1	~R 7 009 indirect	—
CTCb Variant #01 Partial	—	R 6 855	—	—	~24.0 mo	~1	~R 6 855 PFS proxy · indirect	1
Busulfan and Cyclophosphamide Variant #01	—	R 6 777	—	—	—	~1	~R 6 777 indirect	—
Etoposide and TBI Variant #01	—	R 6 770	—	—	—	~1	~R 6 770 indirect	—
Busulfan and Melphalan Variant #01	—	R 5 951	—	—	—	~1	~R 5 951 PFS proxy · indirect	1
FEAM Variant #01 Partial	—	R 5 029	—	—	—	~1	~R 5 029 indirect	—
BEAM Variant #01 Partial	—	R 4 346	—	—	—	~1	~R 4 346 indirect	—
CHUT Variant #01 Partial	—	R 1 504	—	—	—	~1	~R 1 504 indirect	—
Cyclophosphamide and TBI Variant #01	—	R 1 176	—	—	~90.0 mo	~1	~R 1 176 PFS proxy · indirect	2
Melphalan monotherapy Variant #01	—	R 73	42d	~50.0 mo	~22.2 mo	~9	~R 660 PFS proxy · indirect	7
Tandem melphalan Variant #03	—	—	—	~43.0 mo	—	~1	—	8
TAM6 Variant #01	—	—	—	—	—	~1	—	—
Melphalan and TBI Variant #01	—	—	—	—	—	~1	—	—
BCNU/TT Variant #01 Partial	—	—	—	—	—	~1	—	—
TBI Variant #01	—	—	—	—	—	—	—	4

27 of 27 regimens shown